Anti-thrombin III is a naturally occurring inhibitor of blood coagulation that regulates the coagulation cascade. Anti-thrombin III is the type of serine protease inhibitor that inhibits the production of thrombin and other activated serine protease coagulation systems such as factor Xa, IXa and kallikrein. It is an α2-globulin member of the Serpin group and commonly synthesized in liver and is found in plasma and extra vascular sites. Anti-thrombin III influences the inflammatory processes via inhibition of actin polymerization. Testing for the Anti-thrombin II factor is helpful for the patients with recurrent deep vein thrombosis and pulmonary emboli are treated with the anti-thrombin III. In addition, anti-thrombin III testing is also used to treat the conditions such as arterial and venous thrombosis.
The market of anti-thrombin III can be segmented on the basis of:
- By Application
- Dry Chemistry
- Chromogenic Substrates
- DNA Probes
- Monoclonal and Polyclonal Antibodies
- By End Users
- Physician Offices
- Commercial Labs and Private Labs
- Ambulatory Care Centers
The anti-thrombin III market is majorly driven by increasing demand of coagulation testing for anti-thrombin III by end users such as hospitals and physician offices in developed geographies such as North America and Europe. In addition, consistent introduction of novel anti-thrombin III testing methods further drives the growth of the market. Several companies are offering effective and innovative anti-thrombin III testing techniques which would stimulate the market growth. For example, Siemens AG offers Berichrom Antithrombin III (A) reagent that effectively used for the inhibition of the thrombin factor. In addition, the company also offers Sysmex CA-600 Systems that provides efficient clotting, immunologic detection and chromogenic methods and provides easy to use features for the laboratory settings. Thus, this factor would in turn enhance the number of patients utilizing the anti-thrombin III testing methods hence drives the market growth. However, strict regulatory environment and high cost of anti-thrombin III will restrain the anti-thrombin III market growth.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5258
Geographically, North America dominates the global market for Anti-thrombin III. The accelerated growth in North America for anti-thrombin III is mainly attributed to the rising demand of coagulation testing among the patient population coupled with increasing incidence of blood related problems in this region. This factor would in turn establish the healthy to develop the growth of the market hence drives the market growth. Europe is considered as the second largest market of anti-thrombin III owing to the launch of innovation and novel anti-thrombin III testing methods by key players of the market. Launch of new anti-thrombin III testing methods would in turn increase the uptake of these methods which would stimulates the market growth of anti-thrombin III in European region. In addition, India, South East Asia and China are the geographically emerging market for anti-thrombin III and considered to grow with the highest CAGR in near future. Cost effective production environment for biotechnology and pharmaceutical companies compared to developed countries like the U.S. and Europe will attract many biotechnology companies to increase their investment in Asia-Pacific region. Moreover, countries such as India and China would consider as the biggest market for anti-thrombin III due to the high demand for anti-thrombin III testing among the patient population in these regions.
Various key players contributing to the global Anti-thrombin III market comprises Siemens AG, Trinity Biotech PLC, Sysmex Corporation and others.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453